Oric Advances Rinzimetostat Toward First Prostate Cancer Phase 3

An announcement from Oric Pharmaceuticals ( (ORIC) ) is now available.

On March 31, 2026, ORIC Pharmaceuticals presented an update on dose optimization data from its Phase 1b trial of rinzimetostat (ORIC-944) in prostate cancer. The company has selected a 400 mg once-daily dose of rinzimetostat in combination with darolutamide as the provisional Phase 3 regimen, citing a competitive efficacy profile across radiographic progression-free survival and biomarker measures, alongside a notably differentiated safety profile versus rival regimens.

ORIC plans to initiate its first Phase 3 trial of this regimen in post-abiraterone metastatic castration-resistant prostate cancer in the first half of 2026, with additional trials under consideration. By advancing rinzimetostat and its broader clinical pipeline toward registrational studies, ORIC is seeking to strengthen its position in the oncology market and capture a sizable commercial opportunity in a segment it characterizes as lacking well-tolerated oral therapies.

The most recent analyst rating on (ORIC) stock is a Hold with a $11.00 price target. To see the full list of analyst forecasts on Oric Pharmaceuticals stock, see the ORIC Stock Forecast page.

Spark’s Take on ORIC Stock

According to Spark, TipRanks’ AI Analyst, ORIC is a Neutral.

The score is primarily supported by a strong, low-leverage balance sheet and reasonable liquidity, but is held back by the lack of revenue, sizable ongoing losses, and sustained cash burn. Technicals are moderately supportive (longer-term averages and MACD), while valuation metrics are challenged by negative earnings and no dividend yield.

To see Spark’s full report on ORIC stock, click here.

More about Oric Pharmaceuticals

ORIC Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company focused on developing small-molecule therapies for solid tumors. Its pipeline centers on rinzimetostat (ORIC-944), a next-generation PRC2 inhibitor for prostate cancer, and enozertinib (ORIC-114), an EGFR inhibitor for non-small cell lung cancer, both approaching registrational trial starts in large oncology markets.

The company is targeting significant unmet needs such as post-abiraterone metastatic castration-resistant prostate cancer, a U.S. market it estimates at $3.5 billion annually. ORIC positions these programs as potential best-in-class options with differentiated safety and efficacy, particularly aiming to offer oral, well-tolerated regimens where existing therapies have limitations.

Average Trading Volume: 1,658,902

Technical Sentiment Signal: Strong Buy

Current Market Cap: $1.22B

Find detailed analytics on ORIC stock on TipRanks’ Stock Analysis page.